Recruitment for 2 Trials of Investigational ADC for Urothelial Cancer Underway

Share this content:
Enfortumab vedotin is an investigational ADC composed of an anti-Nectin-4 monoclonal antibody attached to monomethyl auristatin E.
Enfortumab vedotin is an investigational ADC composed of an anti-Nectin-4 monoclonal antibody attached to monomethyl auristatin E.

The Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) for patients with locally advanced or metastatic urothelial cancer who have been treated with checkpoint inhibitors (CPI). 

Enfortumab vedotin is an investigational ADC composed of an anti-Nectin-4 monoclonal antibody attached to monomethyl auristatin E, a microtubule-disrupting agent. Enfortumab vedotin targets Nectin-4, which is expressed on many solid tumors, particularly bladder cancers.

The Breakthrough designation was based on interim results from a Phase 1 study which examined enfortumab vedotin as monotherapy in patients with metastatic urothelial cancer who were previously treated with CPIs. The Companies are currently recruiting patients for 2 separate Phase 2 trials for this treatment, one as a monotherapy (EV-201) and one in combination with CPI therapy (EV-103). 

"With the enfortumab vedotin registrational Phase 2 trial and CPI-combination trial actively underway, Astellas looks forward to expanding development of enfortumab vedotin and its oncology pipeline, including treatments that would target some of the hardest-to-treat cancers," said Steven Benner, MD, SVP of Oncology Development at Astellas. 

Enfortumab vedotin is being developed by Astellas Pharma and Seattle Genetics. In addition to urothelial cancer, the Companies are also evaluating enfortumab vedotin in ovarian and non-small cell lung carcinoma.

For more information visit ClinicalTrials.gov.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs